Device company Nemera has announced a partnership with the Research Center for Respiratory Diseases (CEPR) at the University of Tours for investigation of a novel intranasal drug delivery method.
Nemera, which was formerly known as Rexam Healthcare Devices, markets the Advancia line of nasal spray pumps. The company recently announced that it would develop inhaled nanoparticle delivery devices for the treatment of cardiovascular disease as part of Project Cupido
Nemera CEO Marc Haemel commented, “There is no limit to Nemera’s ambition to serve patients. We already market devices in over 40 countries for millions of users. We’ll keep investing in new products and in state-of-the-art manufacturing equipment, to help even more patients with high quality devices all over the world.”
